PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company”), an intellectual property driven biotechnology company focused upon discovery and development of new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today announced the filing of four new U.S. Patent Cooperation Treaty (PCT) Patent Applications seeking to convert five provisional patent applications. This brings the total number of PCT conversion filings completed by Ps
- Mon. Jun 5th, 2023
